Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
作者： Simon Chang-Hao Tsao , Jonathan Weiss , Christopher Hudson , Christopher Christophi , Jonathan Cebon
DOI: 10.1038/SREP11198
关键词:
摘要: We assessed the utility of droplet digital PCR (ddPCR) to evaluate potential using circulating tumour DNA (ctDNA) as a post therapy monitoring tool in melanoma by comparing it serum LDH levels and RECIST scores. ddPCR was shown be reliable distinguishing mutant from wild type alleles with no false positives. Subsequently, we quantified ctDNA (V600EBRAF,V600KBRAF or Q61HNRAS) 6 stage IV patients across several time points during their treatment course. All tested had detectable ctDNA, which exhibited dynamic changes corresponding disease status. The fell upon response rose progression. In our group patients, more consistent informative than blood-based biomarker. addition, BRAF detected could used diagnostically where block unavailable. conclusion, this study demonstrates applicability detect quantify plasma patients.
nature.com
harvard.edu
researchgate.net 
sci-hub.se 
springer.com 参考文章(22)
Maniesh van der Vaart, Piet J. Pretorius, Circulating DNA Annals of the New York Academy of Sciences. ,vol. 1137, pp. 18- 26 ,(2008) , 10.1196/ANNALS.1448.022
M. Fleischhacker, B. Schmidt, Circulating nucleic acids (CNAs) and cancer--a survey. Biochimica et Biophysica Acta. ,vol. 1775, pp. 181- 232 ,(2007) , 10.1016/J.BBCAN.2006.10.001
Lawrence J. Jennings, David George, Juliann Czech, Min Yu, Loren Joseph, Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR The Journal of Molecular Diagnostics. ,vol. 16, pp. 174- 179 ,(2014) , 10.1016/J.JMOLDX.2013.10.007
Julie Wu, Eli Rosenbaum, Shanaz Begum, William H Westra, Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. American Journal of Dermatopathology. ,vol. 29, pp. 534- 537 ,(2007) , 10.1097/DAD.0B013E3181584950
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
Frank Diehl, Kerstin Schmidt, Michael A Choti, Katharine Romans, Steven Goodman, Meng Li, Katherine Thornton, Nishant Agrawal, Lori Sokoll, Steve A Szabo, Kenneth W Kinzler, Bert Vogelstein, Luis A Diaz Jr, Circulating mutant DNA to assess tumor dynamics Nature Medicine. ,vol. 14, pp. 985- 990 ,(2008) , 10.1038/NM.1789
Andreas Behren, Matthew Anaka, Pu-Han Lo, Laura J. Vella, Ian D. Davis, Jenny Catimel, Tracy Cardwell, Craig Gedye, Christopher Hudson, Rodica Stan, Jonathan Cebon, The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel Pigment Cell & Melanoma Research. ,vol. 26, pp. 597- 600 ,(2013) , 10.1111/PCMR.12097
M Sensi, G Nicolini, C Petti, I Bersani, F Lozupone, A Molla, C Vegetti, D Nonaka, R Mortarini, G Parmiani, S Fais, A Anichini, Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene. ,vol. 25, pp. 3357- 3364 ,(2006) , 10.1038/SJ.ONC.1209379
David McDermott, Celeste Lebbé, F. Stephen Hodi, Michele Maio, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson, Charles M. Balch, Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma Cancer Treatment Reviews. ,vol. 40, pp. 1056- 1064 ,(2014) , 10.1016/J.CTRV.2014.06.012
Helen Gogas, AMM Eggermont, Axel Hauschild, Peter Hersey, P Mohr, Dirk Schadendorf, Alan Spatz, Reinhard Dummer, None, Biomarkers in melanoma Annals of Oncology. ,vol. 20, ,(2009) , 10.1093/ANNONC/MDP251